Enanta Pharmaceuticals to Unveil RSV and Asthma Drug Data at ATS 2026
Event summary
- Enanta Pharmaceuticals will present data on zelicapavir for RSV and EPS-3903 for asthma at ATS 2026.
- Oral presentation on zelicapavir's Phase 2 trial results scheduled for May 19, 2026.
- Two posters on EPS-3903's efficacy and distribution in asthma models to be displayed.
- Presentations will be available on Enanta's website post-event.
The big picture
Enanta's focus on small molecule drugs for viral and immunological diseases aligns with the growing demand for targeted therapies. The company's history of successful collaborations, such as with AbbVie on HCV treatments, underscores its ability to navigate complex drug development pathways. The upcoming ATS presentations could validate its pipeline and attract potential partners or investors.
What we're watching
- Clinical Efficacy
- How zelicapavir's Phase 2 results will position it against competitors in the RSV treatment space.
- Market Differentiation
- Whether EPS-3903's selective STAT6 inhibition can carve out a niche in the crowded asthma therapeutics market.
- Regulatory Pathway
- The pace at which Enanta can advance these candidates into later-stage trials based on the ATS 2026 data.
Related topics